In the past few decades, groundbreaking advances have emerged in early diagnosis, treatment, and management of cystic fibrosis (CF), and those with the condition are now living to age 60 and beyond. Why, then, are life insurance companies not yet offering terms to those living with CF?
Munich Re Life US assessed Milliman Irix® – Risk Score with Medical Data, a predictive modeling tool developed and owned by Milliman that assesses mortality risk through the combination of an individual’s prescription drug history and medical claims records.
$2.6 Billion of Protective Value Identified Through Paramed and Laboratory Underwriting Evidence
A recent article published by Clinical Reference Lab and ExamOne showed the protective value for tobacco testing exceeded $4 billion. Using the same time frame (2015-2022) and 18 million record dataset, we now describe the additional value associated with testing for undiagnosed diabetes and hypertension worth $2.6 billion.
Algorithmic Accountability and Proxy Discrimination in Life Insurance – the Regulatory Environment
After looking at Disparate Impact Testing in our previous blog, where we provided background on the concepts of algorithmic accountability and proxy discrimination, this blog will describe the current, evolving regulatory environment and make some projections about the future.